Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BRJ2
UPID:
RM45_HUMAN
Alternative names:
39S ribosomal protein L45, mitochondrial
Alternative UPACC:
Q9BRJ2; A1L436; Q6ZMJ5
Background:
The Large ribosomal subunit protein mL45, also known as 39S ribosomal protein L45, mitochondrial, plays a crucial role in the mitochondrial ribosome. It is involved in protein synthesis within mitochondria, essential for cellular energy production and metabolic processes.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein mL45 could open doors to potential therapeutic strategies. Its pivotal function in mitochondrial protein synthesis makes it a key target for research aimed at addressing mitochondrial disorders.